Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Published on October 5, 2012 at 2:36 AM · No Comments

XenoPort, Inc. (Nasdaq: XNPT) announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF). XP23829 is being developed for the potential treatment of relapsing-remitting multiple sclerosis (RRMS) and/or psoriasis. The trial demonstrated that administration of XP23829 resulted in the expected levels of MMF in the blood. As anticipated, the four formulations produced different PK profiles of MMF, including one formulation that could potentially be dosed two or three times a day and at least one formulation that may be suitable for once-a-day dosing. XP23829 was generally well-tolerated in the trial.

Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, said, "Given the broad potential therapeutic utility of XP23829, we are delighted that the results of this first Phase 1 trial achieved our goals by confirming the expected human metabolism of XP23829 and identifying formulations that we believe could be capable of achieving MMF exposures that are similar to MMF exposures observed in other fumaric acid ester therapies that have demonstrated effectiveness in psoriasis and RRMS. We are particularly pleased that the results suggest that the PK profile of at least one of our formulations supports further evaluation as a once-a-day treatment. We anticipate initiating further studies early next year, including a Phase 1, dose-escalation, multiple-dose study in healthy subjects, with the ultimate goal of developing a potential best-in-class fumaric acid ester-based medicine."

In the Phase 1 trial, 60 subjects were assigned to five cohorts of 12, and each cohort received one of four different formulations of XP23829 or placebo. Subjects received a single dose of XP23829 or placebo in both a fasted and fed state in a randomized order with a two-week period between dosing. All formulations of XP23829 were administered at a dose that was equivalent to 107 mg of MMF. Formulation 1 was a delayed-release formulation that was designed to suppress the release of XP23829 while in the stomach and then immediately release the drug upon entering the small intestine. Formulations 2, 3 and 4 were designed to delay and then slowly release XP23829.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post